Last reviewed · How we verify
Early aspirin Therapy
At a glance
| Generic name | Early aspirin Therapy |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke (PHASE3)
- Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE (PHASE3)
- Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome (PHASE3)
- Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: